Unresectable or metastatic melanoma with progression after ipilimumab or BRAF inhibitor if BRAF V600 mutantIn combination with ipilimumab for unresectable or metastatic melanomaNSCLC with progression on or after platinum therapyMetastatic RCC after prior anti-angiogenic therapycHL: recurrentRecurrent or metastatic squamous cell carcinoma of the head and neckLocally advanced or metastatic urothelial carcinomaMSI-H or mismatch-repair-deficient metastatic colorectal cancerHepatocellular carcinoma. Here, BRAF is linked to renal cell carcinoma.